Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 4 , Pages 419-423 , December 2009

A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma

  • Qinghua Zhou, PhD

      Affiliations

    • Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy，Sichuan University, Chengdu, China
    • West China Hospital, Sichuan University, Chengdu, China
    • These authors contributed equally to this work.
    • ,
  • Xun Sun, PhD

      Affiliations

    • Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy，Sichuan University, Chengdu, China
    • These authors contributed equally to this work.
    • ,
  • Lingyuan Zeng, BS

      Affiliations

    • Sichuan Provincial Cancer Hospital, Chengdu, China
    • ,
  • Jie Liu, PhD

      Affiliations

    • Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy，Sichuan University, Chengdu, China
    • ,
  • Zhirong Zhang, PhD

      Affiliations

    • Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy，Sichuan University, Chengdu, China
    • Corresponding Author InformationCorresponding author. Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China.

Received 31 October 2008 ,Accepted 16 January 2009.

References 

  1. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004;40:1474–1484
  2. Leung TW, Yu S, Johnson PJ, Geschwind J, Vogl TJ, Engelmann K, et al. Phase II study of the efficacy and safety of cisplatin epinephrine injectable gel administered to patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2003;4:652–658
  3. Kim KY. Nanotechnology platforms and physiological challenges for cancer therapeutics. Nanomedicine. 2007;3:103–110
  4. Fernandez-Urrusuno R, Fattal E, Porquet D, Feger J, Couvereur P. Evaluation of liver toxicological effects induced by polyalkylcyanoacrylate nanoparticles. Toxicol Appl Pharmocol. 1995;130:272–279
  5. Shenkenberg TD, Von Hoff DD. Mitoxantrone: a new anti-cancer drug with significant clinical activity. Ann Intern Med. 1986;105:67–81
  6. Zhang ZR, Liao GT, Nagai T, Hou SX. Mitoxantrone polybutyl cyanoacrylate nanoparticles as an anti-neoplastic targeting drug delivery system. Int J Pharm. 1996;139:1–8
  7. Zhang ZR, He Q, Liao GT, Bai SH. Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles. World J Gastroenterol. 1999;5:511–514
  8. World Health Organization (WHO) . WHO toxicity criteria by grade. http://www.accessdata.fda.gov/scripts/cder/onctools/whotox.cfm
  9. Guan Z, Wang Y, Maoleekoonpairoj S, Chen Z, Kim WS, Ratanatharathorn V, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer. 2003;89:1865–1869
  10. Colleoni M, Buzzoni R, Bajetta E, Bochicchio AM, Bartoli C, Audisio R, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer. 1993;72:3196–3201
  11. Jones DV, Patt YZ, Ajani JA, Abbruzzese J, Carrasco CH, Charnsangavej C, et al. A phase I–II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Cancer. 1993;72:2560–2563
  12. Zhang ZR, He Q. Study on liver targeting and hepatocytes permeable valaciclovir polybutylcyanoacrylate nanoparticles. World J Gastroenterol. 1999;5:330–333
  13. Sun X, Wu F, Lu W, Zhang ZR. Study on liver targeting and sustained release hydroxycanptothecin polybutylcyanoacrylate nanoparticles. Pharmazie. 2004;59:791–794
  14. Zimmer A. Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers. Methods. 1999;18:286–295
  15. Kreuter J. Drug targeting with nanoparticles. Eur J Drug Metab Pharmacokinet. 1994;19:253–256
  16. Kattan J, Droz P, Couvreur P, Marino P, Boutan-Laroze A, Rougier P, et al. Polyisobutylcyanoacrylate nanoparticles as drug carriers: influence of sulfur dioxide on the physico-chemical characteristics of ciprofloxacin-and doxorubicin-loaded nanoparticles. Invest New Drugs. 1992;10:191–199
  17. Falkson G, Ryan M, Johnson A, Simson W, Goetzer J, Carbone P, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: an ECOG study. Cancer. 1987;60:2141–2145

 This work was supported by a grant from the National High Research and Development Program of China (863 program) (Grant 2007AA021800).

PII: S1549-9634(09)00047-1

doi: 10.1016/j.nano.2009.01.009

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 4 , Pages 419-423 , December 2009

Article Tools

* Image Usage & Resolution